According to a study published in the European Journal of Cancer, the fairness and equity of datasets for AI-driven mammogram interpretation might be jeopardized by the underrepresentation of racial and ethnic diversity. While AI shows promise for enhancing how mammograms are interpreted, particularly in areas where resources are limited, the study's authors found warning signs regarding the diversity of datasets and the representation of researchers in AI model development, which they said coul

BRIDGEWATER, N.J., April 11, 2025 /PRNewswire/ -- Hamamatsu Photonics, a global leader in whole slide imaging and spatial proteomics solutions, is pleased to announce a strategic partnership with Sirona Dx (SDX) as its Technology Access Partner. This collaboration will streamline the technology evaluation process by providing customers with access to deep spatial biology expertise within a GCLP / CLIA accredited laboratory for imaging, staining, and bioinformatics analysis, removing barriers to

Bipartisan senators introduced the Health Tech Investment Act (S. 1399), which would establish a Medicare reimbursement pathway for FDA-cleared medical devices that utilize artificial intelligence and machine learning. The bill, introduced by Sens. Mike Rounds, R-S.D., and Martin Heinrich, D-N.M., seeks to amend title XVIII of the Social Security Act to "ensure appropriate payment of certain algorithm-based healthcare services under the Medicare program." Through the bill, the Secretary of Heal

MIAMI, April 11, 2025 /PRNewswire/ -- Thomas J. Utset-Ward, MD, has joined the Nicklaus Children's Orthopedic, Sports Medicine & Spine Institute as a pediatric orthopedic surgeon specializing in pediatric orthopedic oncology. His focus is the surgical treatment of benign and malignant tumors of the bone and soft tissues, such as sarcoma, as well as complex limb-sparing reconstructions. Additionally, he specializes in pediatric arthroplasty for children and teens in need of joint replacement surg

Through the Technology in Space Prize, two startups will receive more than $650,000 in total funding and the ability to leverage the ISS National Lab to advance their R&D BOSTON, April 11, 2025 /PRNewswire/ -- Startups RedPoint Oncology and Fourier are the newest recipients of the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space® (CASIS®), manager of the International Space Station (ISS) National Laboratory. Selected through the M assChallenge (

STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB) , a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce the launch of the next generation of Nevisense; Nevisense V. The new platform features an updated user interface, enhanced display resolution, and an upgraded, more user-friendly touchscreen. Beyond these hardware enhancements, Nevisense V offers new features specifically designed for both skin cancer diagn

Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval this week as a first-line treatment for metastatic liver cancer and certain forms of colorectal cancer. Both approvals make the combination available as an earlier option for patients with these cancers. The FDA on Friday approved the two drugs together to treat adult patients with advanced liver cancer based on the results of the CHECKMATE-9DW, which showed Opdivo plus Yervoy as a first-line treatment improved median

NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.2

ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. DWTX Chairman and CEO Greg Duncan stated, “We are pleased that th

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: